These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 17213251

  • 21. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 22. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
    Karanikolas GN, Koukli EM, Katsalira A, Arida A, Petrou D, Komninou E, Fragiadaki K, Zacharioudaki A, Lasithiotakis I, Giavri E, Vaiopoulos G, Sfikakis PP.
    J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
    [Abstract] [Full Text] [Related]

  • 23. Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study.
    Heiberg MS, Rødevand E, Mikkelsen K, Kaufmann C, Didriksen A, Mowinckel P, Kvien TK.
    Ann Rheum Dis; 2006 Oct; 65(10):1379-83. PubMed ID: 16679432
    [Abstract] [Full Text] [Related]

  • 24. Analysis of 4-year Dutch reimbursement application data of biological therapies for psoriatic arthritis.
    Driessen RJ, de Jong EM, Salemink GW, Bürer JH, van de Kerkhof PC, van den Hoogen FH.
    Rheumatology (Oxford); 2010 Mar; 49(3):588-91. PubMed ID: 20040525
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M, Perricone R, Chimenti S, Chimenti MS.
    Dermatology; 2012 Mar; 225(4):312-9. PubMed ID: 23295383
    [Abstract] [Full Text] [Related]

  • 26. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C, Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [Abstract] [Full Text] [Related]

  • 27. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.
    Zisapel M, Zisman D, Madar-Balakirski N, Arad U, Padova H, Matz H, Maman-Sarvagyl H, Kaufman I, Paran D, Feld J, Litinsky I, Wigler I, Caspi D, Elkayam O.
    J Rheumatol; 2015 Jan; 42(1):73-8. PubMed ID: 25399390
    [Abstract] [Full Text] [Related]

  • 28. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD.
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [Abstract] [Full Text] [Related]

  • 29. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
    Söderlin MK, Petersson IF, Geborek P.
    Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371
    [Abstract] [Full Text] [Related]

  • 30. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA.
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [Abstract] [Full Text] [Related]

  • 31. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience.
    Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, Emery P, Marzo-Ortega H.
    Ann Rheum Dis; 2008 May; 67(5):717-9. PubMed ID: 18055476
    [Abstract] [Full Text] [Related]

  • 32. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M, Kievit W, Donders AR, den Broeder AA, Straten VH, Kuper I, Visser H, Jansen TL, Brus HL, Branten AJ, van de Laar MA, van Riel PL.
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [Abstract] [Full Text] [Related]

  • 33. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.
    Kristensen LE, Englund M, Neovius M, Askling J, Jacobsson LT, Petersson IF.
    Ann Rheum Dis; 2013 Oct; 72(10):1675-9. PubMed ID: 23148309
    [Abstract] [Full Text] [Related]

  • 34. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
    van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, Pedersen R, Freundlich B, Fatenejad S.
    Ann Rheum Dis; 2006 Mar; 65(3):328-34. PubMed ID: 16079172
    [Abstract] [Full Text] [Related]

  • 35. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [Abstract] [Full Text] [Related]

  • 36. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
    Kapetanovic MC, Saxne T, Nilsson JA, Geborek P.
    Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
    [Abstract] [Full Text] [Related]

  • 37. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M, Wirthmüller U, Möller B, Villiger PM.
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [Abstract] [Full Text] [Related]

  • 38. Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study.
    Mazzotta A, Esposito M, Schipani C, Chimenti S.
    J Dermatolog Treat; 2009 Jan; 20(6):354-8. PubMed ID: 19954392
    [Abstract] [Full Text] [Related]

  • 39. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
    Iannone F, Lopriore S, Bucci R, Scioscia C, Anelli MG, Notarnicola A, Lapadula G.
    Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
    [Abstract] [Full Text] [Related]

  • 40. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
    Lie E, van der Heijde D, Uhlig T, Mikkelsen K, Kalstad S, Kaufmann C, Rødevand E, Kvien TK.
    Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.